Ring’s immune-evading anelloviruses; plus Tenaya, Goldfinch and Coagulant 

Ring Therapeutics Inc. shared in a bioRxiv preprint a structural analysis of anelloviruses, which are being developed by Ring as gene therapy vectors in cancer, hematology and inflammation indications, shedding light on their immune evading properties. The authors discovered surface features that render the particles less susceptible to antibody neutralization.

Anelloviruses’ potential to evade the immune system could overcome limitations in re-dosing and durability that hamper other gene therapy vectors, including adeno-associated viruses (AAVs) and lentiviruses...